Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers

The Orphan Drug Act

(2016) Michael G. Daniel et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Key cost drivers of pharmaceutical clinical trials in the United States

(2016) Aylin Sertkaya et al.   Clinical Trials

Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy

(2016) Kevin Outterson et al.   HEALTH AFFAIRS

Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review

(2015) Bo Wang et al.   BMJ-British Medical Journal

Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review

(2015) Bo Wang et al.   BMJ-British Medical Journal

Improving the Quality of Cancer Care in an Aging Population

(2013) Arti Hurria   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ethical Considerations in Orphan Drug Approval and Use

(2012) A S Kesselheim   CLINICAL PHARMACOLOGY & THERAPEUTICS

Use Patents, Carve-Outs, and Incentives — A New Battle in the Drug-Patent Wars

(2012) Arti Rai   NEW ENGLAND JOURNAL OF MEDICINE

Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation

(2010) Aaron S. Kesselheim   NEW ENGLAND JOURNAL OF MEDICINE

The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?

(2009) Olivier Wellman-Labadie et al.   HEALTH POLICY

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

(2008) M. C. Heinrich et al.   CLINICAL CANCER RESEARCH

Does orphan drug legislation really answer the needs of patients?

(2008) Marlene E Haffner et al.   LANCET